Teva (NYSE:TEVA) will be responsible for potential commercialization of Uzedy for BP-I. Medincell will be eligible for royalties on net sales. The FDA approved Uzedy for the treatment of ...

Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd, and Medincell announced that the supplemental New Drug Application (sNDA) for Uzedy extended-release injectable suspension ...

and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies ...

New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the most comparable pharmacokinetic (PK ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults in the U.S. The sNDA is based on leveraging ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I ...

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug Application for Uzedy extended-release injectable suspension ...

(NYSE and TASE: TEVA), and Medincell (Euronext (EPA:ENX): MEDCL), announced on February 25, 2025, that the U.S. Food and Drug Administration (FDA) accepted the supplemental New Drug Application (sNDA) ...